Robert E. Reiter, MD, presented “Future Directions (FD) in Molecular Targeted Imaging (MTI) and Theranostics Discussion” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Reiter, Robert E. “Future Directions (FD) in Molecular Targeted Imaging (MTI) and Theranostics Discussion.” August 2024. Accessed Oct 2026. https://grandroundsinurology.com/future-directions-fd-in-molecular-targeted-imaging-mti-and-theranostics-discussion/
Future Directions (FD) in Molecular Targeted Imaging (MTI) and Theranostics Discussion – Summary
Robert E. Reiter, MD, MBA, highlights advances in molecular targeting and imaging in prostate cancer, with a focus on PSMA PET imaging. PSMA PET is expanding its role, particularly in identifying primary or secondary tumors when MRI results are negative or ambiguous. This application, under investigation in the Primary Two study, could reduce unnecessary biopsies and improve tumor detection.
In this 7-minute presentation, Dr. Reiter reviews PSMA-guided surgical resection using fluorescence or radioguidance to enhance precision. He asserts that this approach could reduce positive margins, optimize node removal, and support nerve-sparing techniques when appropriate, improving functional outcomes.
Reiter also discusses PSMA PET in oligometastatic disease, specifically the optimal treatment approach when few metastases are present. In addition, PSMA imaging is being explored in focal and radiation therapies, where it could provide a more accurate assessment of recurrence and treatment response; in advanced prostate cancer, PET could help identify resistant lesions for targeted radiotherapy.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Robert E. Reiter, MD, MBA, is the Bing Professor of Urologic Oncology and a Professor of Molecular Biology at the University of California, Los Angeles, Los Angeles, California. Dr. Reiter also serves as the Director of the Prostate Cancer Program and of Urologic Research, as Chief of the Division of Urologic Oncology, and as Co-Director of the Genitourinary Oncology Program for the Jonsson Cancer Center at the University of California, Los Angeles. He is an internationally recognized expert in all areas of prostate cancer management and research. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans.
